OBJECTIVE: To determine whether the rheumatoid arthritis (RA)-predisposing class II molecules of the major histocompatibility complex (MHC) can present cartilage proteoglycan (PG) aggrecan, and if so, to determine the epitope repertoire of the human cartilage PG in HLA-transgenic mice and determine whether HLA-transgenic mice develop arthritis in response to immunization with human cartilage PG. METHODS: Mice transgenic for HLA-DR2.Ab(0), DR3.Ab(0), DR4.Ab(0), and DQ8.Ab(0), lacking their own (mouse) class II antigens (Ab(0)), on the original (arthritis-resistant) and the arthritis-susceptible BALB/c backgrounds, were immunized with human cartilage PG. The T cell epitope repertoire presented by these class II MHC alleles was determined using a synthetic peptide library (143 peptides of the core protein of human cartilage PG), and arthritis development was monitored and compared in wild-type and HLA-transgenic/congenic BALB/c mice. RESULTS: Mice of the 4 HLA-transgenic lines, either on the original mixed, arthritis-resistant background or DR4.Ab(0)- and DQ8.Ab(0)-transgenic/congenic mice on the arthritis-susceptible BALB/c genetic background, responded well to PG immunization (as assessed by T cell responses and antibody and cytokine production), and a number of T cell epitopes along the core protein of human cartilage PG were identified. DR4.Ab(0)- and DQ8.Ab(0)-transgenic mice immunized with human cartilage PG developed arthritis, but only when these class II MHC molecules were present on the arthritis-susceptible (BALB/c) genetic background. CONCLUSION: A number of human cartilage PG epitopes can be presented by HLA alleles that predispose to the development of RA, but the epitopes of the cartilage PG presented by HLA-DR4 or HLA-DQ8 can induce arthritis only in the presence of an appropriate genetic (non-MHC) background.
OBJECTIVE: To determine whether the rheumatoid arthritis (RA)-predisposing class II molecules of the major histocompatibility complex (MHC) can present cartilage proteoglycan (PG) aggrecan, and if so, to determine the epitope repertoire of the humancartilage PG in HLA-transgenic mice and determine whether HLA-transgenic mice develop arthritis in response to immunization with humancartilage PG. METHODS:Micetransgenic for HLA-DR2.Ab(0), DR3.Ab(0), DR4.Ab(0), and DQ8.Ab(0), lacking their own (mouse) class II antigens (Ab(0)), on the original (arthritis-resistant) and the arthritis-susceptible BALB/c backgrounds, were immunized with humancartilage PG. The T cell epitope repertoire presented by these class II MHC alleles was determined using a synthetic peptide library (143 peptides of the core protein of humancartilage PG), and arthritis development was monitored and compared in wild-type and HLA-transgenic/congenic BALB/c mice. RESULTS:Mice of the 4 HLA-transgenic lines, either on the original mixed, arthritis-resistant background or DR4.Ab(0)- and DQ8.Ab(0)-transgenic/congenic mice on the arthritis-susceptible BALB/c genetic background, responded well to PG immunization (as assessed by T cell responses and antibody and cytokine production), and a number of T cell epitopes along the core protein of humancartilage PG were identified. DR4.Ab(0)- and DQ8.Ab(0)-transgenic mice immunized with humancartilage PG developed arthritis, but only when these class II MHC molecules were present on the arthritis-susceptible (BALB/c) genetic background. CONCLUSION: A number of humancartilage PG epitopes can be presented by HLA alleles that predispose to the development of RA, but the epitopes of the cartilage PG presented by HLA-DR4 or HLA-DQ8 can induce arthritis only in the presence of an appropriate genetic (non-MHC) background.
Authors: Ferenc Boldizsar; Katalin Kis-Toth; Oktavia Tarjanyi; Katalin Olasz; Akos Hegyi; Katalin Mikecz; Tibor T Glant Journal: Arthritis Rheum Date: 2010-10
Authors: Katalin Mikecz; Tibor T Glant; Adrienn Markovics; Kenneth S Rosenthal; Julia Kurko; Roy E Carambula; Steve Cress; Harold L Steiner; Daniel H Zimmerman Journal: Vaccine Date: 2017-06-03 Impact factor: 3.641
Authors: K Olasz; F Boldizsar; K Kis-Toth; O Tarjanyi; A Hegyi; W van Eden; T A Rauch; K Mikecz; T T Glant Journal: Clin Exp Immunol Date: 2012-02 Impact factor: 4.330
Authors: Katalin Kis-Toth; Marianna Radacs; Katalin Olasz; Willem van Eden; Katalin Mikecz; Tibor T Glant Journal: Int Immunol Date: 2012-04-19 Impact factor: 4.823
Authors: Tibor T Glant; Marianna Radacs; Gyorgy Nagyeri; Katalin Olasz; Anna Laszlo; Ferenc Boldizsar; Akos Hegyi; Alison Finnegan; Katalin Mikecz Journal: Arthritis Rheum Date: 2011-05
Authors: T Bárdos; Z Szabó; M Czipri; C Vermes; M Tunyogi-Csapó; R M Urban; K Mikecz; T T Glant Journal: Ann Rheum Dis Date: 2005-01-07 Impact factor: 19.103
Authors: Ferenc Boldizsar; Oktavia Tarjanyi; Katalin Olasz; Akos Hegyi; Katalin Mikecz; Tibor T Glant; Tibor A Rauch Journal: Cardiovasc Pathol Date: 2016-05-17 Impact factor: 2.185
Authors: Jane Falconer; Katie Lowes; Anna L Furmanski; Julian Dyson; Wan Fai Ng; John H Robinson Journal: Immunology Date: 2014-05 Impact factor: 7.397
Authors: Balint Farkas; Ferenc Boldizsar; Oktavia Tarjanyi; Anna Laszlo; Simon M Lin; Gabor Hutas; Beata Tryniszewska; Aaron Mangold; Gyorgy Nagyeri; Holly L Rosenzweig; Alison Finnegan; Katalin Mikecz; Tibor T Glant Journal: Arthritis Res Ther Date: 2009-02-16 Impact factor: 5.156